PV Bulletin

Melanotan II tanning peptide products found to be inconsistently dosed

TGA warns consumers against using Melanotan II tanning products due to inconsistent dosing.

Primary source: Safety monitoring and information

PV Impact Brief

Urgency: HighConfidence: high

What changed

The TGA has issued a warning to consumers against the use of Melanotan II tanning products after laboratory testing confirmed inconsistencies in dosing.

Why it matters

Inconsistent dosing of Melanotan II increases the risk of adverse health events in consumers, emphasizing the need for proper regulation and monitoring of unapproved therapeutic products.

Action needed

Organizations must enhance signal management processes to track and report adverse events related to Melanotan II products, ensuring compliance with safety regulations.

Relevant for
Medical Safety Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 17, 2026

Full briefing

Practical implication

Organizations must enhance signal management processes to track and report adverse events related to Melanotan II products, ensuring compliance with safety regulations.

The TGA has issued a warning against Melanotan II tanning products, highlighting significant health risks linked to inconsistent dosing as laboratory testing reveals variances in the amount of Melanotan II present in seized products.

What changed: The TGA has issued a warning to consumers against the use of Melanotan II tanning products after laboratory testing confirmed inconsistencies in dosing.

Why it matters: Inconsistent dosing of Melanotan II increases the risk of adverse health events in consumers, emphasizing the need for proper regulation and monitoring of unapproved therapeutic products.

Practical implication: Organizations must enhance signal management processes to track and report adverse events related to Melanotan II products, ensuring compliance with safety regulations.

View original source

  • Source: TGA Safety Alerts - Safety information
  • Published at source: 2026-08-17T22:16:00.000Z
  • Discovered by monitor: 2026-08-17T22:23:36.070Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signal#Safety Signals#Australia#Source-ingestion#Regulator-monitor#Tga.gov.au

Related updates for your role

publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated Aug 18, 2026

UK Position Paper on Microbiome-Based Medicinal Products (MBMPs)

Urgency: High

MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.

Signal ManagementCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Position Paper
Read impact briefarrow_forward
publicU.S. Food and Drug Administration · United States · Updated Aug 18, 2026

Regulatory Framework for Generative AI-Enabled Medical Devices

Urgency: High

Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicFDA · United States · Updated Aug 19, 2026

Guidance on Developing Cellular and Gene Therapy Products

Urgency: High

Clinical safety and pharmacovigilance teams should review the FDA guidance and adjust their monitoring plans to ensure they align with the newly provided recommendations regarding safety endpoints and data collection processes.

Signal ManagementLiterature SurveillanceRegulatory Intelligence Lead
SOP Impact3 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicTherapeutic Goods Administration (TGA) · Australia · Updated Aug 19, 2026

Enforcement action disrupts illicit vape distribution network in Sydney

Urgency: High

Ongoing investigations into unlawful vaping products are expected to result in further enforcement actions, including additional seizures and potential penalties for non-compliance with the Therapeutic Goods Act.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward